5-iodobenzo[b]furan-2-carboxylic acid | 1144854-04-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: 5-iodobenzo[b]furan-2-carboxylic acid
• 英文别名: 5-iodobenzofuran-2-carboxylic acid；5-iodo-1-benzofuran-2-carboxylic acid
• CAS: 1144854-04-5
• 化学式: C₉H₅IO₃
• 分子量: 288.041
• InChiKey: KQOZGMVAKCVJHO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  50.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-iodobenzo[b]furan-2-carboxylic acid 在 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成
  参考文献：
  名称：

  一系列有力和选择性的线性速激肽NK2受体拮抗剂对C和N末端部分的调节

  摘要：

  本文中，我们描述了一系列新的有效速激肽NK的合成2通过ibodutant的C-和N-末端部分的调制（MEN 15596，受体拮抗剂1）。N末端的苯并[ b ]噻吩环被不同的取代萘和苯并呋喃取代，同时在C末端的四氢吡喃部分评估了进一步的修饰。大多数化合物表现出对人NK 2受体的高亲和力和体外拮抗剂的高效力，表明可以在分子的两个末端引入广泛的取代基，而不会影响与NK 2受体的相互作用。对选定的化合物进行了体内测试，证实了其作为NK的活性2个拮抗剂。特别是，对豚鼠静脉内和静脉内给药后，化合物61b能够拮抗NK 2诱导的结肠收缩，其作用力和作用持续时间与参考化合物1（MEN 15596，ibodutant）完全相同。

  DOI：

  10.1002/cmdc.200900389
• 作为产物：
  描述：

  ethyl 5-iodobenzofuran-2-carboxylate 在 potassium hydroxide 、 盐酸 作用下， 以 乙醇 、 水 为溶剂， 反应 1.0h， 以66%的产率得到5-iodobenzo[b]furan-2-carboxylic acid
  参考文献：
  名称：

  N-(4-(4-(2,3-Dichloro- or 2-methoxyphenyl)piperazin-1-yl)butyl)heterobiarylcarboxamides with Functionalized Linking Chains as High Affinity and Enantioselective D3 Receptor Antagonists

  摘要：

  In the present report, the D3 receptor pharmacophore is modified in the 2,3-diCl- and 2-OCH3-phenylpiperazine class of compounds with the goal to improve D3 receptor affinity and selectivity. This extension of structure-activity relationships (SAR) has resulted in the identification of the first enantioselective D3 antagonists (R- and S-22) to be reported, wherein enantioselectivity is more pronounced at D3 than at D2, and that a binding region on the second extracellular loop (E2) may play a role in both enantioselectivity and D3 receptor selectivity. Moreover, we have discovered some of the most D3-selective compounds reported to date that show high affinity (K-i = 1 nM) for D3 and similar to 400-fold selectivity over the D2 receptor subtype. Several of these analogues showed exquisite selectivity for D3 receptors over >60 other receptors, further underscoring their value as in vivo research tools. These lead compounds also have appropriate physical characteristics for in vivo exploration and therefore will be useful in determining how intrinsic activity at D3 receptors tested in vitro is related to behaviors in animal models of addiction and other neuropsychiatric disorders.

  DOI：

  10.1021/jm900095y

文献信息

• Synthesis and in vitro evaluation of tetrahydroisoquinolines with pendent aromatics as sigma-2 (σ₂) selective ligands
  作者：Mark E. Ashford、Vu H. Nguyen、Ivan Greguric、Tien Q. Pham、Paul A. Keller、Andrew Katsifis

  DOI：10.1039/c3ob42254b

  日期：——

  Sigma-2 selective ligands – a SAR study showing increased potency and selectivity with derivatives showing the potential to be converted into radiolabelled ligands.

  Sigma-2 选择性配体 - 一项结构活性关系研究表明，衍生物的效力和选择性增加，有潜力转化为放射标记配体。
• Linear basic compounds having nk-2 antagonist activity and formulations thereof
  申请人：——

  公开号：US20040259930A1

  公开（公告）日：2004-12-23

  Described herein are compounds of formula (I) useful as antagonists of tachykinins in general, and in particular of neurokinin A; and the pharmaceutical formulations comprising the compounds of formula (I) 1

  本文描述了式（I）化合物，可作为缓激肽拮抗剂，特别是神经激肽A的拮抗剂，并且包括含有式（I）化合物的药物制剂。
• LINEAR BASIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTIVITY AND FORMULATIONS THEREOF
  申请人：Malesci Istituto Farmacobiologico S.p.A.

  公开号：EP1442050B1

  公开（公告）日：2006-09-13
• PHARMACEUTICAL COMPOSITIONS BASED ON NK2 ANTAGONISTS FOR PEDIATRIC USE
  申请人：Laboratori Guidotti S.P.A.

  公开号：EP1809267A1

  公开（公告）日：2007-07-25
• Pharmaceutical Compositions Based on Nk2 Antagonists for Pediatric Use
  申请人：Aleotti Alberto

  公开号：US20080090795A1

  公开（公告）日：2008-04-17

  Pharmaceutical compositions containing NK2 antagonists are described, useful for the treatment of infantile colics.